

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

东曜药业

TOT BIOPHARM International Company Limited

東曜藥業股份有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1875)

APPOINTMENT OF CHIEF OPERATING OFFICER

The board of directors (the “**Board**”) of TOT BIOPHARM International Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Liu, Jun (“**Dr. Liu**”) has been appointed as the chief operating officer of the Company (“**COO**”) with effect from 21 April 2020. Dr. Liu will be fully responsible for the management of the Group’s operations, as well as assisting the general manager in promoting the development of overseas operations.

Dr. Liu joined the Group on 17 October 2016 as a vice general manager, and has served as an executive director and chief scientific officer of the Company since October 2018 and March 2019 respectively. He is responsible for the research and development (“**R&D**”) and quality control of products. With Dr. Liu’s vast experience of overseas R&D and management, the Board believes that the appointment of Dr. Liu as COO will be conducive to improving and enhancing the Group’s internal collaboration between R&D and production in preparation for its entry into the phase of commercialization development in the future, and at the same time strengthening the Group’s exploration of overseas R&D and international collaboration projects.

The Board would like to congratulate Dr. Liu on his new position.

The biographical details of Dr. Liu are as follows:

Dr. Liu, aged 52, joined the Group on 17 October 2016 as a vice general manager and was appointed as an executive director on 26 October 2018 and chief scientific officer on 12 March 2019. He is also a member of the Strategy Committee. He is responsible for the new drug development and quality control system of biological drugs.

Prior to joining the Group, Dr. Liu was the executive director of biologics research and development department in Shanghai ChemPartner Co., Ltd. between July 2010 and October 2016. Prior to that, he was employed by Bayer US LLC between April 2005 and July 2010 working with Bayer Healthcare as a senior scientist in the United States.

Dr. Liu obtained a Ph.D. in bioanalytical chemistry from the University of California, Davis in the United States in December 2002 and a bachelor's degree in chemistry from the University of Science & Technology of China in Hefei, Anhui Province, China in July 1991.

As at the date of this announcement, Dr. Liu does not have any relationship with any director, senior management, substantial shareholder or controlling shareholder (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited) of the Company. Save as disclosed above, he has not held any other directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years.

By Order of the Board
TOT BIOPHARM International Company Limited
Yeh-Huang, Chun-Ying
Executive Director

Hong Kong, 21 April 2020

As at the date of this announcement, the executive directors of the Company are Ms. Yeh-Huang, Chun-Ying and Dr. Liu, Jun; the non-executive directors of the Company are Mr. Fu, Shan, Dr. Kung, Frank Fang-Chien, Mr. Kang, Pei and Mr. Qiu, Yu Min; and the independent non-executive directors of the Company are Ms. Hu, Lan, Dr. Sun, Lijun Richard and Mr. Chang, Hong-Jen.